These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9653838)

  • 1. Treatment of pulmonary embolism by subcutaneous low-molecular-weight heparin in a hemodialysis patient.
    Szeto CC; Wang AY; Lui SF; Lai KN; Yu AW
    Am J Nephrol; 1998; 18(4):325-8. PubMed ID: 9653838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
    Belcaro G; Nicolaides AN; Cesarone MR; Laurora G; De Sanctis MT; Incandela L; Barsotti A; Corsi M; Vasdekis S; Christopoulos D; Lennox A; Malouf M
    Angiology; 1999 Oct; 50(10):781-7. PubMed ID: 10535716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.
    Nurmohamed MT; van Riel AM; Henkens CM; Koopman MM; Que GT; d'Azemar P; Büller HR; ten Cate JW; Hoek JA; van der Meer J; van der Heul C; Turpie AG; Haley S; Sicurella A; Gent M
    Thromb Haemost; 1996 Feb; 75(2):233-8. PubMed ID: 8815566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations.
    Bellosta R; Ferrari P; Luzzani L; Carugati C; Cossu L; Talarico M; Sarcina A
    Angiology; 2007; 58(3):316-22. PubMed ID: 17626986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of central venous catheter-associated thrombosis: a meta-analysis.
    Kirkpatrick A; Rathbun S; Whitsett T; Raskob G
    Am J Med; 2007 Oct; 120(10):901.e1-13. PubMed ID: 17904462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Right atrial thrombus due to internal jugular vein catheter.
    Ram R; Swarnalatha G; Rakesh Y; Jyostna M; Prasad N; Dakshinamurty KV
    Hemodial Int; 2009 Jul; 13(3):261-5. PubMed ID: 19614782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients.
    Egger B; Schmid SW; Naef M; Wildi S; Büchler MW
    Dig Surg; 2000; 17(6):602-609. PubMed ID: 11155006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Internal jugular, subclavian, and axillary deep venous thrombosis and the risk of pulmonary embolism.
    Major KM; Bulic S; Rowe VL; Patel K; Weaver FA
    Vascular; 2008; 16(2):73-9. PubMed ID: 18377835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of venous thromboembolism in cancer patients.
    Lee AY; Levine MN
    Oncology (Williston Park); 2000 Mar; 14(3):409-17, 421; discussion 422, 425-6. PubMed ID: 10742967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparin in the treatment of pulmonary embolism.
    Ageno W; Turpie AG
    Semin Vasc Surg; 2000 Sep; 13(3):189-93. PubMed ID: 11005462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants.
    DeLoughery TG
    Crit Care Clin; 2005 Jul; 21(3):497-512. PubMed ID: 15992670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low molecular weight heparin for deep vein thrombosis in glioma patients.
    Schmidt F; Faul C; Dichgans J; Weller M
    J Neurol; 2002 Oct; 249(10):1409-12. PubMed ID: 12382158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of low molecular weight heparins for treating non-massive pulmonary embolism].
    Charbonnier B; Pacouret G
    Presse Med; 1994 Dec; 23(39):1821-5. PubMed ID: 7899306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The insufficiency of low molecular weight heparin (LMWH) prophylaxis in patients with hereditary antithrombin (AT) deficiency].
    Dybowska M; Kuca P; Gralec R; Burakowski J; Tomkowski WZ
    Pneumonol Alergol Pol; 2007; 75(3):278-82. PubMed ID: 17966105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies in pulmonary embolism and deep venous thrombosis.
    Davidson BL
    Am Fam Physician; 1999 Nov; 60(7):1969-80. PubMed ID: 10569501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The low molecular weight heparin on rat pulmonary surfactant associated protein A of acute pulmonary embolism].
    Liu CP; Lu WX; Liu WG; Chen HW; Wang C
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(9):634-6. PubMed ID: 17550736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.